Journal article 111 views 6 downloads
Improving the DSM-5 approach to cognitive impairment: developmental prosopagnosia reveals the need for tailored diagnoses
Behavior Research Methods
Swansea University Author: Edwin Burns
-
PDF | Accepted Manuscript
Download (1.03MB)
DOI (Published version): 10.3758/s13428-024-02459-4
Abstract
The Diagnostic Statistical Manual of Mental Disorders 5th edition (DSM-5) approach to neurocognitive disorders recommends diagnosing cognitive impairment when a patient scores beyond -1 SD below neurotypical norms on two cognitive tests. I review how this approach will fail due to cognitive tests’ p...
Published in: | Behavior Research Methods |
---|---|
Published: |
2024
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa66634 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract: |
The Diagnostic Statistical Manual of Mental Disorders 5th edition (DSM-5) approach to neurocognitive disorders recommends diagnosing cognitive impairment when a patient scores beyond -1 SD below neurotypical norms on two cognitive tests. I review how this approach will fail due to cognitive tests’ power limitations, validity issues, imperfect reliabilities, and biases, before summarising their resulting negative consequences. As a proof of concept, I use developmental prosopagnosia, a condition characterised by difficulties recognising faces, to show the DSM-5 only diagnoses 62-70% (n1 = 61, n2 = 165) versus 100% (n1 = 61) through symptoms alone. Pooling the DSM-5 missed cases confirmed the presence of group-level impairments on objective tests, which were further evidenced through meta-analyses, thus validating their highly atypical symptoms. These findings support a paradigm shift towards bespoke diagnostic approaches for distinct cognitive impairments, including a symptom-based method when validated effective. I reject dogmatic adherence to the DSM-5 approach to neurocognitive disorders, and underscore the importance of a data driven, transdiagnostic approach to understanding patients’ subjective cognitive impairments. This will ultimately benefit patients, their families, clinicians, and scientific progress. |
---|---|
College: |
Faculty of Medicine, Health and Life Sciences |
Funders: |
Swansea University |